Fertility after Bilateral Cryptorchidism
Lee P.A.b · Coughlin M.T.a
Evaluation by Paternity, Hormone, and Semen Data
aGraduate School of Public Health, University of Pittsburgh, Pa., and bPenn State Milton S. Hershey Medical Center, Hershey, Pa., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Purpose: Evaluation of the fertility of a cohort of formerly bilaterally cryptorchid men in comparison with a group of formerly unilaterally cryptorchid men, and a group of control men. Materials and Methods: Using a detailed questionnaire concerning paternity and factors related to paternity, a cohort of formerly bilateral cryptorchid men were studied and compared with men who had undergone orchiopexy for unilateral cryptorchidism, and a group of control men. All study subjects had had surgery at the Children’s Hospital of Pittsburgh, Pittsburgh, Pa., between 1955 and 1975. A subset of the full cohort underwent clinical evaluation that included a physical examination, serum hormonal determination and semen analyses. Results: Paternity rates are significantly lower among the formerly bilaterally cryptorchid men who have attempted to father a child (65.3%) as compared to the formerly unilaterally cryptorchid (89.7%; p < 0.001) and control men (93.2%; p < 0.001). Differences in the ability to father children are also apparent when semen and hormone levels are compared between the three groups. The bilateral group has significantly lower sperm density and inhibin B levels, and higher FSH and LH levels, than the unilateral and control groups. Conclusions: Men born with bilateral cryptorchidism have severely compromised fertility in adulthood. This reduction in fertility is clearly shown in comparisons of both paternity rates, and in semen and hormone analyses, between the formerly bilateral, formerly unilateral, and control groups.
© 2001 S. Karger AG, Basel
- Berkowitz GS, Lapinski RH, Dolgin SE, Gazella JG, Bodian CA, Holzman IR: Prevalence and natural history of cryptorchidism. Pediatrics 1993;92:44–49.
Scorer CG: The descent of the testis. Arch Dis Child 1964;39:605–609.
Gross RE, Jewett TC: Surgical experience from 1,222 operations for undescended testes. JAMA 1956;160:634–641.
Gilhooly PE, Meyers F, Lattimer JK: Fertility prospects for children with cryptorchidism. AJDC 1984;138:940–943.
- Fallon B, Kennedy TJ: Long-term follow-up fertility in cryptorchid patients. Urology 1985;25:502–504.
- Kumar D, Bremner DN, Brown PW: Fertility after orchiopexy for cryptorchidism: A new approach to assessment. Br J Urol 1989;64:516–520.
Cendron M, Keating MA, Huff DS, Kopp CE, Snyder HMcC III, Duckett JW: Cryptorchidism, orchiopexy and infertility: A critical long-term retrospective analysis. J Urol 1989;142:599–562.
- Lee PA, O’Leary LA, Songer NJ, Coughlin MT, Bellinger MF, LaPorte RE: Paternity after bilateral cryptorchidism: A controlled study. Arch Pediatr Adolesc Med 1997;151:260–263.
Carver JH: Bilateral orchiopexy and fertility. Proc R Soc Med 1958;51:328–330.
Bramble FJ, Houghton AL, Eccles S, O’Shea A, Jacobs HS: Reproductive and endocrine function after surgical treatment of bilateral cryptorchidism. Lancet 1974;i:311–314.
Puri P, O’Donnell B: Semen analysis of patients who had orchidopexy at or after seven years of age. Lancet 1988;ii:1051–1052.
- Okuyama A, Nonomura N, Nakamura M, et al: Surgical management of undescended testis: Retrospective study of potential fertility in 274 cases. J Urol 1989;142:749–751.
- Mandat KM, Wieczorkiewicz B, Gubata-Katcata M, Sypniewshki J, Bujok G: Semen analysis of patients who had orchiopexy in childhood. Eur J Pediatr Surg 1994;4:94–97.
- Singer R, Dickerman Z, Sagiv M, Laron Z, Livini E: Endocrinological parameters and cell-mediated immunity post-operation for cryptorchidism. Arch Androl 1988;20:153–157.
- Yavetz H, Harash B, Paz G, Yogev L, Jaffa AJ, Lessing JB, Homonnai ZT: Cryptorchidism: Incidence and sperm quality in infertile men. Andrologia 1992;24:293–297.
- Lee PA, Bellinger MA, Coughlin MT: Correlations among hormone levels, sperm parameters and paternity in formerly unilaterally cryptorchid men. J Urol 1998;160:1155–1157.
Pierik FH, Vreeburg JTM, Stijnen T, DeJong FH, Weber RFA: Serum inhibin B as a marker of spermatogenesis. J Clin Enndocr Metab 1998;83:3110–3114.
Anawalt BD, Bebb RA, Matsumoto AM, Groome NP, Illingworth PJ, McNeilly AS, Bremner WJ: Serum inhibin B levels reflect Sertoli cell function in normal men and men with testicular dysfunction. J Clin Endocr Metab 1998;83:3341–3345.
- Jensen TK, Andersson AM, Hjollund NHI, Scheike T, Kolstad H, Giwercman A, Henriksen TB, Ernst E, Bonde JP, Olsen J, McNeilly J, Groome NP, Skakkebbæk NE: Inhibin B as a serum marker of spermatogenesis: Correlation to differences in sperm concentration and follicle-stimulating hormone levels. A study of 349 Danish men. J Clin Endocr Metab 1997;82:4059–4063.
- Lee PA, Bellinger MF, Coughlin MT: Correlations among hormone levels, sperm parameter and paternity in formerly unilaterally cryptorchid men. J Urol 1998;160:1155–1157.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.